Chemotherapy
IL-2 receptor upregulation by arginine butyrate increases DAB(389)IL-2 toxicity
Published in Cancer Weekly, February 18th, 2003
According to recent research from the United States, "DAB(389)IL-2 (ONTAK) is a fusion protein consisting of the ADP-ribosyltransferase and membrane translocating domains of native diphtheria toxin and the full length sequence for interleukin-2 (IL-2) gene. In vitro data demonstrates that DAB389IL-2 is cytotoxic to cells expressing the high affinity IL-2 receptor (IL-2R). In Phases I and II clinical trials of patients whose tumor cells express a component of the IL-2R, the response rates were 18% for B-cell non-Hodgkin lymphoma (NHL) and 30% for cutaneous T-cell lymphoma (CTCL).
"In this study, we examined the effects of arginine butyrate on IL-2R expression and...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
Source: Cancer Weekly (2003-02-18)
More Articles from Cancer Weekly
- Cell Biology
Newly discovered cellular process helps cells respond to DNA damage - Kidney Cancer
Minimally invasive treatment successfully destroys tumors - Chronic Myelogenous Leukemia
Feto-maternal microchimerism enables safe, effective mismatched stem cell transplants - Mammography
Modulation transfer function improves diagnosis of dense breast tissues - Melanoma
Study sheds light on how the sun causes skin cancer - Stem Cell Research
Neural progenitors effective vehicle for glioma treatment - More from this issue of Cancer Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
